248 related articles for article (PubMed ID: 25522678)
1. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma.
Mataki H; Seki N; Chiyomaru T; Enokida H; Goto Y; Kumamoto T; Machida K; Mizuno K; Nakagawa M; Inoue H
Int J Oncol; 2015 Mar; 46(3):1039-50. PubMed ID: 25522678
[TBL] [Abstract][Full Text] [Related]
2. Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.
Kumamoto T; Seki N; Mataki H; Mizuno K; Kamikawaji K; Samukawa T; Koshizuka K; Goto Y; Inoue H
Int J Oncol; 2016 Nov; 49(5):1870-1880. PubMed ID: 27633630
[TBL] [Abstract][Full Text] [Related]
3. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N
J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691
[TBL] [Abstract][Full Text] [Related]
4. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
5. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma.
Moriya Y; Nohata N; Kinoshita T; Mutallip M; Okamoto T; Yoshida S; Suzuki M; Yoshino I; Seki N
J Hum Genet; 2012 Jan; 57(1):38-45. PubMed ID: 22089643
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C.
Mataki H; Enokida H; Chiyomaru T; Mizuno K; Matsushita R; Goto Y; Nishikawa R; Higashimoto I; Samukawa T; Nakagawa M; Inoue H; Seki N
J Hum Genet; 2015 Feb; 60(2):53-61. PubMed ID: 25518741
[TBL] [Abstract][Full Text] [Related]
10. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
Liu L; Shao X; Gao W; Zhang Z; Liu P; Wang R; Huang P; Yin Y; Shu Y
FEBS J; 2012 Oct; 279(20):3800-12. PubMed ID: 22883469
[TBL] [Abstract][Full Text] [Related]
12. Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma.
Mataki H; Seki N; Mizuno K; Nohata N; Kamikawaji K; Kumamoto T; Koshizuka K; Goto Y; Inoue H
Oncotarget; 2016 Nov; 7(44):72084-72098. PubMed ID: 27765924
[TBL] [Abstract][Full Text] [Related]
13. Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma.
Mizuno K; Seki N; Mataki H; Matsushita R; Kamikawaji K; Kumamoto T; Takagi K; Goto Y; Nishikawa R; Kato M; Enokida H; Nakagawa M; Inoue H
Int J Oncol; 2016 Feb; 48(2):450-60. PubMed ID: 26676674
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA‑206 exerts anti‑oncogenic functions in esophageal squamous cell carcinoma by suppressing the c‑Met/AKT/mTOR pathway.
Zhang J; Fa X; Zhang Q
Mol Med Rep; 2019 Mar; 19(3):1491-1500. PubMed ID: 30569129
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
17. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Michikoshi H; Nakamura T; Sakai K; Suzuki Y; Adachi E; Matsugo S; Matsumoto K
Cancer Lett; 2013 Jul; 335(2):472-8. PubMed ID: 23507559
[TBL] [Abstract][Full Text] [Related]
18. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
